Meta-Analysis Confirms Increased Cardiovascular Risk with Rosiglitazone

Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses – The BMJ (free)

Commentaries: The power of shared data to better understand drug safety – The BMJ Opinion (free) AND New study adds to evidence of diabetes drug link to heart problems – BMJ (free) AND Largest ever evaluation of the cardiovascular risk of rosiglitazone published – OnMedica (free) AND Individual patient data analysis firms up rosiglitazone safety verdict – medwire News (free)